Breaking News, Collaborations & Alliances

Orchard & SIRION Enter License Agreement

SIRION to provide Orchard with a license to its proprietary lentiviral transduction enhancer LentiBOOST™

Orchard Therapeutics and SIRION Biotech GmbH have entered into a license agreement, through which Orchard has licensed SIRION’s LentiBOOST™ technology to enhance manufacturing efficiency for certain of Orchard’s ex vivo autologous hematopoietic stem cell gene therapy drug candidates.   “At Orchard Therapeutics, we are establishing manufacturing capabilities to deliver potentially transformative gene therapy products to rare disease patients around the globe. Optimization of lentiviral transdu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters